Role of Continuous Subcutaneous Insulin Infusion in Patients with Recalcitrant Diabetes in South India
| العنوان: | Role of Continuous Subcutaneous Insulin Infusion in Patients with Recalcitrant Diabetes in South India |
|---|---|
| المؤلفون: | Ranjit UnnikrishnanI, Kavitha Rao, Viswanathan Mohan, Ranjit Mohan Anjana, Thangamani Suresh, Chidambarann Sudhakaran |
| المصدر: | Diabetes Technology & Therapeutics. 11:733-737 |
| بيانات النشر: | Mary Ann Liebert Inc, 2009. |
| سنة النشر: | 2009 |
| مصطلحات موضوعية: | Adult, Blood Glucose, Male, Insulin pump, medicine.medical_specialty, Adolescent, Diabetic ketoacidosis, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, India, Hypoglycemia, Infusions, Subcutaneous, Medical Records, Body Mass Index, chemistry.chemical_compound, Insulin Infusion Systems, Endocrinology, Internal medicine, Diabetes mellitus, medicine, Humans, Hypoglycemic Agents, Insulin, Aged, Glycated Hemoglobin, business.industry, Medical record, Middle Aged, medicine.disease, Surgery, Medical Laboratory Technology, Diabetes Mellitus, Type 1, Postprandial, Diabetes Mellitus, Type 2, chemistry, Female, Glycated hemoglobin, business |
| الوصف: | We aimed to assess the effect of continuous subcutaneous insulin infusion (CSII) therapy in patients with "recalcitrant diabetes" whose glycemia had not been controlled adequately with multiple daily injections of insulin or insulin plus oral hypoglycemic agents.We retrospectively analyzed the medical records of patients with diabetes who were initiated on insulin pump therapy at our center in India between 2002 and 2007. Data analysis included fasting and postprandial blood glucose and glycated hemoglobin (HbA1c) values, insulin requirement, body weight, and the occurrence of hypoglycemia and diabetic ketoacidosis.We studied 33 patients with diabetes (type 1 [n = 17] and type 2 [n = 16]) who were on CSII therapy for a mean duration of 3.4 years. A statistically significant reduction in HbA1c was found after initiating CSII (prepump 10.7% vs. postpump 8.3%, P0.001). The reduction was greater in type 1 patients (10.6 +/- 2.1 vs. 8.0 +/- 1.6%) than in type 2 patients (11.0 +/- 2.1 vs. 8.8 +/- 1.4%). There was a reduction in frequency of severe hypoglycemia after starting the CSII pump, and there were no instances of diabetic ketoacidosis.Although HbA1c levels did not reach optimal targets, our data indicate that CSII is an effective therapy for patients with diabetes having recalcitrant diabetes who can afford this treatment and whose glycemia is poorly controlled with conventional therapies. |
| تدمد: | 1557-8593 1520-9156 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::037d7a4044dc92c8faaa15e92a3207dfTest https://doi.org/10.1089/dia.2009.0066Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....037d7a4044dc92c8faaa15e92a3207df |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15578593 15209156 |
|---|